Overview Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma Status: Completed Trial end date: 2015-11-25 Target enrollment: Participant gender: Summary Evaluate the safety and tolerability of a single dose of S-1226 (8%) in subjects with mild atopic asthma. Phase: Phase 2 Details Lead Sponsor: SolAeroMed Inc.